Revenue miss vs consensus is notable but the FDA label expansion and positive BCG-naive trial data support a larger addressable market. Monitor Q4 revenue trajectory and the upcoming sBLA submission for BCG-naive NMIBC, which could significantly expand the patient population.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $7.11entry
- T+1 · 7d ago −5.13%α −4.77% · $6.75
- T+5 · 17h ago −15.89%α −14.20% · $5.98
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ImmunityBio reported Q3 2026 net product revenue of $48.7M, up 53% YoY, but missed consensus revenue estimates of $59.2M. The company also announced FDA label expansion for ANKTIVA in BCG-unresponsive NMIBC and positive Phase 2/3 data, while GAAP net loss widened to $184.6M driven by non-cash fair value changes. Cash and marketable securities stood at $334.3M.
Key Financial Metrics
Key Facts
- Q3 2026 net product revenue $48.7M, up 53% YoY from $31.8M
- First nine months 2026 net product revenue $143.6M, up 92% YoY
- Revenue miss: actual $48.7M vs consensus $59.2M
- FDA expanded ANKTIVA label on Oct 14, 2026 to include papillary-only NMIBC
- QUILT-2.005 trial in BCG-naive NMIBC met primary endpoint; sBLA submission on track for Q4 2026
- ANKTIVA approved in Israel, first patients treated in Europe
- GAAP net loss $184.6M vs $67.3M YoY, driven by non-cash fair value changes
- Adjusted net loss $97.9M vs $72.4M YoY
- Cash and marketable securities $334.3M as of Sep 30, 2026
- Operating cash burn $75.3M in Q3 2026
Financial Impact
Q3 net product revenue $48.7M (missed consensus $59.2M by 17.7%); GAAP net loss $184.6M; adjusted net loss $97.9M; cash burn $75.3M
Risk Factors
- Revenue miss of 17.7% vs consensus may pressure near-term sentiment
- GAAP net loss widening due to non-cash fair value changes from stock price increase
- Adjusted net loss also increased YoY, indicating rising operating costs
- Cash burn of $75.3M per quarter; cash runway limited without additional financing or revenue acceleration
- Dependence on continued ANKTIVA adoption and regulatory approvals
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001326110-26-000097 |
| Document: ibrx-20261109.htm | 0001326110-26-000097 |
| Document: 0001326110-26-000097-index-headers.html | 0001326110-26-000097 |
| Document: 0001326110-26-000097-index.html | 0001326110-26-000097 |
| Document: 0001326110-26-000097.txt | 0001326110-26-000097 |
| 8-K Data (Synthetic) | 0001326110-26-000097 |
Track record
11 reports on IBRX
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +19.12% at T+60 after the Apr 9, 2026 report. 2 of 5 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 5/10 Viewing Entry $7.11 Now $5.98 −15.89% settles Feb 5
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $7.11 Now $5.98 −15.89% settles Feb 5
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $8.93 Now $5.98 −33.03% settles Feb 2
- Oct 14, 20264w ago 8-K Bullish 7/10 Entry $10.00 Now $5.98 −40.20% settles Jan 12
- Aug 4, 202614w ago 8-K Neutral 5/10 Entry $6.95 to $8.63 Now $5.98 −13.96% ▲ +24.17% +24.39% vs SPY
- Jul 6, 202619w ago Insider Cluster Neutral 2/10 Entry $8.76 to $9.44 Now $5.98 −31.74% ▲ +7.76% +5.77% vs SPY
- Jul 1, 202619w ago Insider Cluster Neutral 2/10 Entry $9.44 to $8.52 Now $5.98 −36.65% ▼ −9.75% −12.54% vs SPY
- May 18, 202626w ago 8-K Bullish 5/10 Entry $7.76 to $7.65 Now $5.98 −22.94% ▼ −1.42% −7.71% vs SPY
- Apr 9, 202631w ago 8-K Bullish 8/10 Entry $7.48 to $8.91 Now $5.98 −20.05% ▲ +19.12% +8.34% vs SPY
- Apr 6, 202632w ago 8-K Neutral 4/10 Entry $7.08 to $9.20 Now $5.98 −15.54% ▲ +29.94% +16.47% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers